NY-NTT-COMMUNICATIONS
NTT Communications Corporation (NTT Com), the global data and IP services arm of Fortune Global 500 telecom leader NTT (TYO: 9432), announced that it is further expanding its DDoS Protection Services (DPS) with the addition of DPS Max. The new solution is the most advanced tier of service for Global IP Network (GIN) customers that require full protection from DDoS attacks, including attack detection and auto-mitigation capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181202005046/en/
DDoS attacks can strike at any time, potentially crippling network infrastructure and severely degrading the performance and reachability of a website or other IP-accessible system. Depending upon the type and severity of an attack, the impact can result in significant losses in revenue and damaged assets and, most importantly, in unpleasant experiences for end users.
“The security and protection of our network and our customers’ networks is a top priority for our company,” said Michael Wheeler, executive vice president of the NTT Communications Global IP Network at NTT America. “We are focused on providing a wide-ranging suite of services and tools for network security and protection, including mitigation of DDoS attacks and black hole filtering. DPS Max enhances our offering and gives customers more solution options and the opportunity to choose the level of support they need.”
NTT Com’s DPS product suite also includes DPS Control, DPS Core and DPS Detect. DPS Control is an entry-level tier of service intended for customers that don’t require full mitigation assistance. DPS Core is the initial level of service for customers that need full DDoS mitigation support. DPS Detect provides an advanced level of service as it adds detection capabilities to help identify potential attacks using state-of-the-art technology while working with customer-defined thresholds.
The new DPS Max offers the highest level of service and provides the features of DPS Core and DPS Detect, while adding automatic mitigation capabilities. With auto-mitigation, Global IP Network customers are able to have an attack mitigated immediately because the company’s DDoS mitigation platform detects attacks and automatically initiates mitigations based upon customer-defined thresholds. When the platform notices that an attack has ended, it automatically stops the mitigation, returning the customer’s traffic to their normal, pre-attack routing.
Subscribers to DPS Max have access to the Network Security Team, the same expert team responsible for keeping the tier-1 Global IP Network infrastructure safe and secure, and also enjoy exclusive use of the company’s DPS Portal, a platform where they can review past mitigation reports and request configuration changes, among many features.
About NTT Communications Corporation
NTT Communications solves the world’s technology challenges by helping enterprises overcome complexity and risk in their ICT environments with managed IT infrastructure solutions. These solutions are backed by our worldwide infrastructure, including industry leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 400,000m2 of the world’s most advanced data center facilities. Our global professional services teams provide consultation and architecture for the resiliency and security required for your business success, and our scale and global capabilities are unsurpassed. Combined with NTT DATA, NTT DOCOMO, NTT Security, and Dimension Data, we are NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com
About NTT Communications Global IP Network
Consistently ranked among the top networks worldwide, NTT Com’s Tier-1 Global IP Network covers North and South America, Asia, Europe and Oceania, and provides the best possible environment for content, data and video transport through a single autonomous system number (AS 2914).
NTT Com was recently named Best North American Wholesale Carrier at the Global Carrier Awards 2018 for the fifth consecutive year. The company has also won the Best Global Wholesale Carrier (Data) award twice in the last five years.
www.gin.ntt.net | Twitter@GinNTTnet #globalipnetwork #AS2914
View source version on businesswire.com: https://www.businesswire.com/news/home/20181202005046/en/
Contact:
Fernando Costantino Global IP Network NTT Communications | NTT America +1-425.250.7051 fcostantino@us.ntt.net
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom